CA-125 and D-dimer show potential applications in diagnosing and managing adenomyosis. As a traditional tumor marker, CA-125 may show a trend of increase in patients with adenomyosis, but its specificity is insufficient, because it may also increase in various gynecological diseases. As a measure of coagulation activity, D-dimer may be associated with inflammation and tissue changes related to adenomyosis. However, its specific mechanism of action and diagnostic efficacy still need to be further studied. Current studies are limited by the small sample size, insufficient standardization and lack of dynamic monitoring data, these factors limit the general applicability of the conclusions and practical value of the application. Therefore, it is particularly urgent to conduct large-scale, prospective studies to verify the effectiveness of these biomarkers and to explore their combined application in the diagnosis and management of adenomyosis. This will help to develop more accurate diagnosis and treatment plans and enhance the scientificity of clinical decision-making.